Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Wild-Type Hras Suppresses the Earliest Stages of Tumorigenesis in a Genetically Engineered Mouse Model of Pancreatic Cancer.

PloS one - 1 Jan 2015

Weyandt Jamie D, Lampson Benjamin L, Tang Sherry, Mastrodomenico Matthew, Cardona Diana M, Counter Christopher M

Abstract excerpt

Oncogenic, activating mutations in KRAS initiate pancreatic cancer. There are, however, two other Ras family members, Nras and Hras, which can be activated in the presence of oncogenic Kras. The role of these wild-type Ras proteins in cancer remains unclear, as their disruption has been shown to enhance or inhibit tumorigenesis depending upon the context. As pancreatic cancer is critically dependent upon Ras...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinogenesis
Share to Cell Proliferation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, Transgenic

Share to Pancreatic Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Share to Signal Transduction

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 26452271
DOI: 10.1371/journal.pone.0140253
PMCID: PMC4599940

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Wild-Type Hras Suppresses the Earliest Stages of Tumorigenesis in a Genetically Engineered Mouse Model of Pancreatic Cancer.PMID 26452271Read ↗

Dynamic Regulation of Expression of KRAS and Its Effectors Determines the Ability to Initiate Tumorigenesis in Pancreatic Acinar Cells.Semantic proximity Read ↗

Roles for KRAS in pancreatic tumor development and progression.Semantic proximity Read ↗

Kras mutation rate precisely orchestrates ductal derived pancreatic intraepithelial neoplasia and pancreatic cancerSemantic proximity Read ↗

Kras as a key oncogene and therapeutic target in pancreatic cancerSemantic proximity Read ↗

Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse.Semantic proximity Read ↗

Mutant KRAS in the initiation of pancreatic cancer.Semantic proximity Read ↗

KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition.Semantic proximity Read ↗

A New Strategy to Control and Eradicate “Undruggable” Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Developmental and Evolutionary BiologySemantic proximity Read ↗

The Significance of Ras Activity in Pancreatic Cancer InitiationSemantic proximity Read ↗

Ductal pancreatic cancer interception by FGFR2 abrogationSemantic proximity Read ↗

Notch and Kras in pancreatic cancer: at the crossroads of mutation, differentiation and signaling.Semantic proximity Read ↗

Hedgehog/Ras interactions regulate early stages of pancreatic cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.